Daiwa Securities Group Inc. Has $6.66 Million Position in Insmed, Inc. $INSM

Daiwa Securities Group Inc. increased its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 961.6% during the 4th quarter, Holdings Channel.com reports. The fund owned 38,251 shares of the biopharmaceutical company’s stock after acquiring an additional 34,648 shares during the period. Daiwa Securities Group Inc.’s holdings in Insmed were worth $6,657,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in INSM. Norges Bank acquired a new stake in shares of Insmed during the 4th quarter valued at about $506,625,000. Vanguard Group Inc. boosted its position in shares of Insmed by 13.0% during the 3rd quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock valued at $2,870,957,000 after acquiring an additional 2,291,328 shares in the last quarter. Artisan Partners Limited Partnership lifted its holdings in Insmed by 49.0% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after purchasing an additional 1,623,342 shares during the last quarter. Orbis Allan Gray Ltd bought a new position in Insmed during the 2nd quarter valued at about $153,389,000. Finally, Darwin Global Management Ltd. lifted its holdings in Insmed by 5.8% during the 3rd quarter. Darwin Global Management Ltd. now owns 20,457,445 shares of the biopharmaceutical company’s stock valued at $2,897,797,000 after purchasing an additional 1,112,824 shares during the last quarter.

Insider Activity at Insmed

In other Insmed news, CFO Sara Bonstein sold 2,404 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total value of $245,857.08. Following the completion of the transaction, the chief financial officer directly owned 69,082 shares of the company’s stock, valued at approximately $7,065,016.14. The trade was a 3.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Roger Adsett sold 88,060 shares of the business’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the completion of the transaction, the chief operating officer directly owned 106,810 shares of the company’s stock, valued at approximately $17,584,130.30. This represents a 45.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 160,482 shares of company stock valued at $24,438,193. Insiders own 2.10% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on INSM shares. Barclays lifted their price target on shares of Insmed from $231.00 to $237.00 and gave the company an “overweight” rating in a report on Wednesday, April 1st. Stifel Nicolaus lifted their price target on shares of Insmed from $205.00 to $208.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Wells Fargo & Company cut their price target on shares of Insmed from $177.00 to $160.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Mizuho lifted their price target on shares of Insmed from $204.00 to $206.00 and gave the company an “outperform” rating in a report on Wednesday, March 25th. Finally, Leerink Partners lifted their price target on shares of Insmed from $210.00 to $215.00 and gave the company an “outperform” rating in a report on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Insmed currently has a consensus rating of “Moderate Buy” and an average price target of $210.50.

Insmed Stock Performance

Shares of NASDAQ INSM opened at $94.22 on Monday. Insmed, Inc. has a 1-year low of $70.57 and a 1-year high of $212.75. The company has a market cap of $20.42 billion, a PE ratio of -16.39 and a beta of 0.79. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. The company has a 50-day moving average of $130.45 and a two-hundred day moving average of $154.65.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.14. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The company had revenue of $305.96 million during the quarter, compared to the consensus estimate of $300.81 million. During the same period in the previous year, the firm posted ($1.42) earnings per share. The company’s revenue was up 229.7% on a year-over-year basis. As a group, equities analysts expect that Insmed, Inc. will post -2.56 earnings per share for the current fiscal year.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.